Many biological processes are mediated by interactions between proteins. Accordingly, investigations of these binding reactions are of growing importance and can assist in the development of drugs that target specific interacting proteins. For example, the extensive growth of blood vessels that occurs during cancer (1 ), rheumatoid diseases, and ocular diseases (2, 3 ) requires a protein-signaling cascade. Disruption of this cascade causes tumor hypoxia, for example, and hence facilitates treatment. A number of antiangiogenic drugs are undergoing clinical trials at the National Cancer Institute (4 ). Vascular endothelial growth factor A (VEGF-A) 5 (165-amino acid residue form) signaling is a very promising target for antiangiogenic cancer therapies, because this protein circulates in the blood and acts directly on endothelial cells as a powerful regulator of tumor angiogenesis (5) (6) (7) . VEGF-A binds to 2 related receptor tyrosine kinases, VEGF receptor 1 [VEGFR-1 (Flt-1)] and VEGFR-2 (KDR). VEGFR-2 induces proliferation, survival, and vascular permeability, whereas VEGFR-1 may trap VEGF-A, preventing it from signaling (8 ) .
Examples of bioassays that measure the growth of blood vessels and the effects of specific inhibitors include in vitro assays of endothelial cell migration (9 ) and proliferation (10 ) , and the in vivo cornea pocket assay for observing vascularization of the normally avascular cornea (11 ) .
Automated in vitro high-throughput screening techniques are required to evaluate large libraries of drug candidates, such as those created via combinatorial chemical synthesis. There is a compelling need for miniaturized screening assays that reduce reagent consumption and lower assay costs. Assay miniaturization in turn necessitates increased sensitivity because the assay volumes and numbers of molecules are reduced. Homogeneous assays that involve only sequential additions of reagents and no separation steps are desirable for high-throughput screening of drug candidates (12 ) . The scintillation proximity assay is a commonly used homogeneous-phase technique for monitoring ligand binding to immobilized receptors (13 ) . The method is based on the binding of a radioactive ligand to receptors immobilized on the surface of microbeads in close proximity to the scintillants. The radiation produced by the bound ligand leads to scintillant excitation, which is observable as light emission.
The proximity ligation assay (PLA) is a recently developed technique based on detecting proteins with the help of specific probes that contain conjugated DNA. The proteins are thereby reported as DNA signatures that can easily be detected and quantified by the PCR. Upon the coincident binding of pairs of affinity probes to a target protein, the attached DNA strands are brought in proximity to be joined by ligation, giving rise to specific amplifiable DNA strands. PLA permits highly specific and sensitive solution-phase detection of proteins in 1-L samples. This approach has been useful for detecting cytokines, growth factors, and infectious agents in complex biological samples (14 - (A), When the target protein (VEGF-A, pink ovals) is bound by a pair of proximity probes, the free ends of the oligonucleotide extensions of the affinity probes are brought into proximity. The added connecting oligonucleotide binds to both DNA fragments and assembles their 5Ј and 3Ј ends, whereupon the 2 strands are ligated by DNA ligase. The produced product is amplified and detected by real-time PCR. (B), The target protein VEGF-A is incubated with a soluble VEGFR (blue rectangles). On binding of VEGF-A to the receptor, the latter dimerizes, and VEGF-A becomes inaccessible to the proximity probes, producing a loss of signal in the PLA tests. (C), VEGF-A is incubated with the soluble VEGFR in the presence of an inhibitor (green square) that competes with VEGF-A for receptor binding. Therefore, VEGF-A remains free and accessible to the proximity probes, generating a signal in the PLA tests. (D), When an inhibitor binds directly to the VEGF-A protein, the proximity probes are displaced, producing a loss of PCR signal.
)
, and several target molecules can be investigated in parallel in the same reaction (18 ) .
We describe the use of PLA to monitor VEGF-A binding to 2 of its receptors, VEGFR-1 and VEGFR-2, and we demonstrate the applicability of this assay for the sensitive detection of the effects of agents that disrupt these interactions. We analyzed 6 different inhibitors: a DNA aptamer, a mixed DNA/RNA aptamer, a monoclonal VEGF-A neutralizing antibody, a monoclonal antibody directed against VEGFR-2, a recombinant competitive protein, and a low molecular weight synthetic molecule.
Materials and Methods

PROXIMITY LIGATION REAGENTS AND INHIBITORS
Recombinant human VEGF-A 165 protein, soluble receptors VEGFR-1 and VEGFR-2, neutralizing VEGF-A monoclonal antibody, a recombinant competitive protein (placental growth factor), and biotinylated affinity-purified polyclonal VEGF-A antibodies were all purchased from R&D Systems. A neutralizing VEGFR-2 monoclonal antibody (C27) was generously provided by ImClone Systems (New York, NY).
The VEGF-A aptamer t22-OMe was purchased from Interactiva (ThermoHybaid). The aptamer sequence is a mixed DNA/RNA oligonucleotide sequence with modified 2Ј RNA residues: 5Ј-P-GC AACGATGA"GCGgUaGGAAGAAUUGGAAGCGC" AACATCACCC-3Ј. The nucleotides between the quotation marks are RNA. All of the U and C residues in this part of the sequence had a 2Ј fluoro group, and all As and Gs are 2Ј O-methyl-modified except for the nucleotides represented by lowercase letters, which indicate the normal 2Ј-OH RNA.
The platelet-derived growth factor DNA aptamer 41t (5Ј-TACTCAGGGCACTGCAAGCAATTGTGGT CCCAATGGGCTGAGTA-3Ј) was purchased from Interactiva (ThermoHybaid).
PROXIMITY PROBES
Proximity probes with free 3Ј or 5Ј ends were created by conjugating thiol-modified oligonucleotides to maleimide-derivatized streptavidin (STV). The conjugates were subsequently reacted with biotinylated VEGF-A antibodies as described elsewhere (14 ) . The oligonucleotide sequences were as follows: 5ЈfreeSTV, 5Ј-PTCGTGTCTAAAGTCCGTTACCTTGATTCCCC TAACCCTCTTGAAAAATTCGGCATCGGTGA-3Ј; 3ЈSTV, 5Ј-CGCATCGCCCTTGGACTACGACTGAC GAACCGCTTTGCCTGACTGATCGCTAAATCGTG-3ЈOH.
PROXIMITY LIGATION ANALYSIS OF VEGF-A INHIBITION
We incubated 1 L of 1 pmol/L VEGF-A with 1 L of inhibitor together with 50 pmol/L 5ЈfreeSTV and 3ЈfreeSTV in a total volume of 6 L at 37°C for 1 h. We then added 45 L of a combined mix for ligation and amplification Weiss units of T 4 DNA ligase (Fermentas), 400 nmol/L connector oligonucleotide (5Ј-TACTTAGACACGA CACGATTTAGTTT-3Ј; biomers.net), 80 mol/L ATP, 200 mol/L of each deoxynucleoside triphosphate, 100 nmol/L of each primer (forward, 5Ј-CATCGCCCT TGGACTACGA-3Ј; reverse, 5Ј-GGGAATCAAGGTA ACGGACTTTAG-3Ј; biomers.net), 100 nmol/L TaqMan® MGB probe (5Ј-FAM-TGACGAACCGCTTTGCCTG ACTGA-MGBNFQ-3Ј; Applied Biosystems), and 1.5 U Platinum Taq DNA polymerase (Invitrogen)]. After the addition of the combined mix, the tubes were sealed with optical PCR lids (Applied Biosystems) and transferred to a real-time PCR instrument, either Stratagene's MX 3000P or the ABI 7000 from Applied Biosystems. The reaction conditions consisted of an initial incubation at 95°C for 2 min, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. The results were presented either as threshold cycle (C T ) values or as signal-to-noise ratios (the number of ligations of proximity probe pairs that occurred in the sample divided by the number of ligations in the negative control).
PROXIMITY LIGATION ANALYSIS OF VEGFR-2 INHIBITION
We preincubated 1 L of 1 nmol/L VEGFR-2 with 1 L of inhibitor for 30 min at 37°C. We then added 1 L of 1 pmol/L VEGF-A together with 50 pmol/L of 5ЈfreeSTV and 3ЈfreeSTV to the first incubation (6 L total) and incubated further for 1 h at 37°C. The ligation and PCR steps were carried out as outlined above. 
CELL CULTURE AND IMMUNOBLOTTING
Porcine aortic endothelial cells that stably produce VEGFR-2 (PAE/KDR.11) were cultured in Ham's F-12 medium (Invitrogen) containing 100 mL/L fetal calf serum (Invitrogen). For analysis of VEGFR-2 phosphorylation, we seeded 0.75 ϫ 10 5 cells per 6-cm dish. After a 24-h incubation, we serum-starved the cells for an additional 24 h in Ham's F-12 medium containing 1 mL/L fetal calf serum and then stimulated them with VEGF-A (PeproTech) in the absence or presence of inhibitors of VEGF-A/VEGFR-2 function. The cells were lysed in 0.5 mL lysis buffer (50 mmol/L HEPES, pH 7.5, 100 mmol/L NaCl, 1 mmol/L EGTA, 100 mol/L Na 3 VO 4 , 10 mg/L aprotinin, 0.1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L dithiothreitol, and 10 mL/L Triton X-100). Cleared lysates were immunoprecipitated with VEGFR-2 antibodies (R&D Systems). Immunoprecipitates and 30 L of cell lysates (approximately 25 g) were separated by SDS-PAGE and electrophoretically transferred onto Hybond-C Extra membranes (GE Healthcare/Amersham Biosciences). The membranes were then blocked in PBS (containing 137 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L Na 2 HpO 4 , and 2 mmol/L KH 2 PO 4 ) containing 30 g/L bovine serum albumin (Roche). Phosphorylation of VEGFR-2 was visualized with PY20 phosphotyrosine antibodies (UBI), and equal loading of lysates was confirmed with ␤-actin antibodies (Santa Cruz Biotechnology). Finally, we incubated the membranes with the appropriate secondary antibodies conjugated to horseradish peroxidase (GE Healthcare/Amersham Biosciences) and visualized immune reactivity with an en- 
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hanced chemiluminescence detection system (ECL; GE Healthcare/Amersham Biosciences).
DATA ANALYSIS
The proximity ligation reactions were performed in triplicate. The results presented in the figures are mean percentages of the maximum signal generated by VEGF-A alone. The signals were calculated as the numbers of ligations of the proximity probe pairs in the samples. The immunoblots represent the results of at least 2 independent experiments. The half-maximal inhibitory concentration (IC 50 ) (i.e., the inhibitor concentration required for 50% inhibition of the target) was estimated for all of the inhibitors.
Results
We have used PLA to investigate the effects of 6 inhibitors on the binding of VEGF-A to its receptors, VEGFR-1 and VEGFR-2, and we have compared these results with those obtained by immunoprecipitation of VEGFR-2 from VEGFR-2-overproducing cells treated with VEGF-A and the same inhibitors. Fig. 1 presents an overview of how the study was performed and how the results were calculated. The signal generated by the detection of VEGF-A (Fig. 1A) is lost when VEGF-A is incubated with a soluble VEGFR (Fig. 1B) , because the protein is no longer accessible to the proximity-probe conjugates after binding and dimerization of the receptors. In contrast, VEGF-A remains free and available for detection by proximity probes when VEGF-A is incubated with the receptor in the presence of an inhibitor that competes for binding to the receptor or that hinders its dimerization (Fig. 1C) . Finally, in the presence of an inhibitor that binds directly to VEGF-A, the protein becomes inaccessible for the proximity probes, leading to a loss in signal (Fig. 1D) .
First, we analyzed the binding of 1 pmol/L VEGF-A to VEGFR-1 and to VEGFR-2 ( Fig. 2A) . VEGF-A showed substantially stronger binding to VEGFR-1 than to VEGFR-2. This result is in accordance with the results of Shibuya et al. (19 ) , who reported the affinity of VEGF-A for VEGFR-1 to be quite high (K d ϭ 10 pmol/L), compared with VEGFR-2 (K d ϭ 100 pmol/L) (20 ) . A dose-response curve for ligand-induced phosphorylation of VEGFR-2 was obtained for a range of VEGF-A concentrations (Fig. 2B) . On the basis of these results, we subsequently used 30 nmol/L VEGF-A for receptor stimulation in analyses of the effects of various inhibitory agents (with the exception of the VEGF-A aptamer, for which we had to use a concentration of 10 nmol/L to detect a clear effect of this inhibitor).
We investigated the effects of 2 inhibitors that bind directly to VEGF-A: the VEGF-A aptamer t22-OMe discovered by Ruckman et al. (21 ) and a commercially available neutralizing VEGF-A monoclonal antibody. We used the aptamer 41t, which is capable of binding with high affinity to the ␤ chain of the platelet-derived growth factor protein (22 ) , as a negative control; it did not inhibit VEGF-A detection (Fig. 3A) . The IC 50 value for the aptamer and the antibody was approximately (Fig. 3B) .
We next analyzed the effect of a monoclonal antibody that inhibits the interaction between VEGF-A and VEGFR-2 by binding to the receptor and preventing its dimerization. Placental growth factor was used as a negative control. This protein competes with VEGF-A for binding to VEGFR-1, but it does not bind to VEGFR-2 ( Fig. 4A) (8 ) . The IC 50 dose for the neutralizing VEGFR-2 antibody was approximately 5 nmol/L when 1 pmol/L of VEGF-A was incubated with 1 nmol/L of VEGFR-2. The IC 50 estimate for VEGFR-2 phosphorylation in cells was approximately 3 nmol/L (Fig. 4B) .
Besides protein-and nucleic acid-based inhibitors, we also analyzed the inhibitory effects of a low molecular weight VEGF-A inhibitor, GFA-116 (23 ) (Fig. 5A) . The IC 50 for GFA-116 was 5 mol/L when 1 pmol/L of VEGF-A was incubated with 1 nmol/L of VEGFR-2. The IC 50 value for the effect of GFA-116 on VEGFR-2 phosphorylation (Fig. 5B ) was approximately 1 mol/L.
Discussion
We have demonstrated that PLA is suitable for monitoring interactions between growth factors and their receptors, in this case VEGF-A binding to its receptors VEGFR-1 and VEGFR-2, and for analyzing the effects of agents that disrupt such interactions. The results obtained with PLA correlate well with results obtained when the effects of inhibitors were evaluated by measuring VEGFR-2 phosphorylation, although the observed IC 50 values for the inhibitors were generally higher with the latter method. The discrepancy can be explained either by the lower VEGF-A concentrations used in the PLA or by the complexity of the cellular environment in the phosphorylation studies affecting the inhibition process. The specificity of the results was ascertained by the use of inhibitors against related proteins that served as negative controls.
The successful characterization of VEGF-Abinding inhibitors implies a general applicability for PLA, which is especially convenient for large-scale screenings. Large arrays of inhibitors are tested each year, yet only a few of them (e.g., antiangiogenic compounds) reach clinical trials. There is a major need for improvements in the secondary screening of drug candidates, because separate systems are often required to evaluate the effects with maximal accuracy. Proteinprotein interactions are considered difficult targets for inhibition screening, and PLA may offer significant advantages over conventional methods. For example, PLA allows extremely sensitive and specific label-free detection of proteins in 1-L sample volumes, thereby reducing reagent expenditures by a factor of 1 000 compared with regular sandwich ELISAs.
CONCLUSIONS
PLA is a promising approach for the automated analysis of protein interactions and the screening of inhibitor libraries. The technique allows evaluation of the apparent affinity (IC 50 ) from a dose-response curve. The total time of a PLA (including DNA amplification and analysis) is 3 h, with minimal manual work and reagent additions. Finally, an in situ variant of PLA (24 ) can be used to visualize drug effects at the cellular level in tissue samples collected from treated individuals.
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